SEARCH:   Advanced

Blood, 1 April 2008, Vol. 111, No. 7, pp. 3322-3330. This Article Full Text Full Text (PDF) Erratum (v112,p452) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Reed, J. C. Search for Related Content PubMed PubMed Citation Articles by Reed, J. C. Related Collections ASH 50th Anniversary Reviews Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  ASH 50TH ANNIVERSARY REVIEW Bcl-2–family proteins and hematologic malignancies: history and future prospects John C. Reed1 1 Burnham Institute for Medical Research, La Jolla, CA BCL-2 was the first antideath gene dis-covered, a milestone that effectively launched a new era in cell death research. Since its discovery more than 2 decades ago, multiple members of the human Bcl-2 family of apoptosis-regulating proteins have been identified, including 6 antiapoptotic proteins, 3 structurally similar proapoptotic proteins, and several structurally diverse proapoptotic interacting proteins that operate as upstream agonists or antagonists. Bcl-2–family proteins regulate all major types of cell death, including apoptosis, necrosis, and autophagy. As such, they operate as nodal points at the convergence of multiple pathways with broad relevance to biology and medicine. Bcl-2 derives its name from its original discovery in the context of B-cell lymphomas, where chromosomal translocations commonly activate the BCL-2 protooncogene, endowing B cells with a selective survival advantage that promotes their neoplastic expansion. The concept that defective programmed cell death contributes to malignancy was established by studies of Bcl-2, representing a major step forward in current understanding of tumorigenesis. Experimental therapies targeting Bcl-2 family mRNAs or proteins are currently in clinical testing, raising hopes that a new class of anticancer drugs may be near. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. V. Kurtova, K. Balakrishnan, R. Chen, W. Ding, S. Schnabl, M. P. Quiroga, M. Sivina, W. G. Wierda, Z. Estrov, M. J. Keating, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance Blood, November 12, 2009; 114(20): 4441 - 4450. [Abstract] [Full Text] [PDF] D. Hermanson, S. N. Addo, A. A. Bajer, J. S. Marchant, S. G. K. Das, B. Srinivasan, F. Al-Mousa, F. Michelangeli, D. D. Thomas, T. W. LeBien, et al. Dual Mechanisms of sHA 14-1 in Inducing Cell Death through Endoplasmic Reticulum and Mitochondria Mol. Pharmacol., September 1, 2009; 76(3): 667 - 678. [Abstract] [Full Text] [PDF] M. P. Quiroga, K. Balakrishnan, A. V. Kurtova, M. Sivina, M. J. Keating, W. G. Wierda, V. Gandhi, and J. A. Burger B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406 Blood, July 30, 2009; 114(5): 1029 - 1037. [Abstract] [Full Text] [PDF] M. Niedermeier, B. T. Hennessy, Z. A. Knight, M. Henneberg, J. Hu, A. V. Kurtova, W. G. Wierda, M. J. Keating, K. M. Shokat, and J. A. Burger Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach Blood, May 28, 2009; 113(22): 5549 - 5557. [Abstract] [Full Text] [PDF] M. H. Kang and C. P. Reynolds Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy Clin. Cancer Res., February 15, 2009; 15(4): 1126 - 1132. [Abstract] [Full Text] [PDF] X. Deng, F. Gao, and W. S. May Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding Blood, January 8, 2009; 113(2): 422 - 428. [Abstract] [Full Text] [PDF] E. G.E. de Vries and S. de Jong Exploiting the Apoptotic Route for Cancer Treatment: A Single Hit Will Rarely Result in a Home Run J. Clin. Oncol., November 10, 2008; 26(32): 5151 - 5153. [Full Text] [PDF] F. J. Tan, M. Husain, C. M. Manlandro, M. Koppenol, A. Z. Fire, and R. B. Hill CED-9 and mitochondrial homeostasis in C. elegans muscle J. Cell Sci., October 15, 2008; 121(20): 3373 - 3382. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020